NCT01979523 2026-03-19
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT01587352 2026-03-18
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00020475 2024-03-04
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT01835145 2022-08-04
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02129075 2021-11-16
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02363283 2020-08-21
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01413191 2020-02-19
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00121225 2019-01-29
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01814046 2018-10-11
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00243061 2018-08-27
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00450255 2018-05-24
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00482911 2017-03-27
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00109005 2017-01-02
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089063 2015-04-15
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00329641 2014-07-31
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00489944 2014-01-10
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01217398 2013-08-26
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00032045 2013-06-20
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00288041 2013-03-05
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062933 2012-08-20
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed